IC
Ikarian Capital Portfolio holdings
AUM
$302M
This Quarter Return
+7.96%
1 Year Return
+65.21%
3 Year Return
+441.33%
5 Year Return
+548.26%
10 Year Return
–
AUM
$322M
AUM Growth
+$322M
(+0.48%)
Cap. Flow
-$129M
Cap. Flow
% of AUM
-40.09%
Top 10 Holdings %
Top 10 Hldgs %
44.05%
Holding
134
New
20
Increased
8
Reduced
29
Closed
9
Top Buys
| 1 |
Viridian Therapeutics
VRDN
|
$11.4M |
| 2 |
Ultragenyx Pharmaceutical
RARE
|
$9.94M |
| 3 |
Arcus Biosciences
RCUS
|
$9.16M |
| 4 |
Spyre Therapeutics
SYRE
|
$8.89M |
| 5 |
Avalo Therapeutics
AVTX
|
$8.7M |
Top Sells
| 1 |
Sarepta Therapeutics
SRPT
|
$18.7M |
| 2 |
Soleno Therapeutics
SLNO
|
$11.3M |
| 3 |
Nuvalent
NUVL
|
$10.2M |
| 4 |
Crinetics Pharmaceuticals
CRNX
|
$8.27M |
| 5 |
Amgen
AMGN
|
$8.06M |
Sector Composition
| 1 | Healthcare | 99.61% |
| 2 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Olema Pharmaceuticals
OLMA
$432M
| $1.1M | 0.15% |
+92,000
| New | +$1.1M |
|
52
InflaRx
IFRX
$117M
| $1.08M | 0.15% |
704,987
| – | – |
|
53
Sagimet Biosciences
SGMT
$239M
| $1.07M | 0.15% |
387,565
-25,000
| -6% | -$69.3K |
|
54
Jasper Therapeutics
JSPR
$44.2M
| $1.04M | 0.14% |
55,175
-50,000
| -48% | -$941K |
|
55
BiomX
PHGE
$14.1M
| $911K | 0.13% |
+893,000
| New | +$911K |
|
56
Delcath Systems
DCTH
$381M
| $906K | 0.13% |
100,370
| – | – |
|
|
CLYM
57
Climb Bio, Inc. Common Stock
CLYM
$165M
| $891K | 0.12% |
175,100
+75,100
| +75% | +$382K |
|
58
Amylyx Pharmaceuticals
AMLX
$877M
| $890K | 0.12% |
274,551
| – | – |
|
59
ProQR Therapeutics
PRQR
$256M
| $880K | 0.12% |
483,583
| – | – |
|
60
Cartesian Therapeutics
RNAC
$267M
| $841K | 0.12% |
52,193
-190,177
| -78% | -$3.07M |
|
61
Kezar Life Sciences
KZR
$28.5M
| $827K | 0.12% |
1,068,992
+200,000
| +23% | +$155K |
|
|
VERV
62
DELISTED
Verve Therapeutics
VERV
| $823K | 0.11% |
+170,000
| New | +$823K |
|
63
Immunic
IMUX
$79.4M
| $814K | 0.11% |
493,496
| – | – |
|
|
ITOS
64
DELISTED
iTeos Therapeutics
ITOS
| $802K | 0.11% |
78,574
| – | – |
|
|
JBIO
65
Jade Biosciences, Inc. Common Stock
JBIO
$245M
| $769K | 0.11% |
367,965
| – | – |
|
66
Veru
VERU
$48.5M
| $728K | 0.1% |
946,382
| – | – |
|
67
Lyell Immunopharma
LYEL
$220M
| $726K | 0.1% |
526,066
| – | – |
|
68
Milestone Pharmaceuticals
MIST
$151M
| $708K | 0.1% |
466,019
| – | – |
|
69
Acumen Pharmaceuticals
ABOS
$84.2M
| $661K | 0.09% |
266,435
| – | – |
|
70
Inhibrx
INBX
$403M
| $660K | 0.09% |
42,123
-187,877
| -82% | -$2.94M |
|
|
ALLK
71
DELISTED
Allakos
ALLK
| $635K | 0.09% |
972,675
| – | – |
|
72
Immatics
IMTX
$662M
| $564K | 0.08% |
49,415
| – | – |
|
|
NYXH
73
Nyxoah
NYXH
$220M
| $484K | 0.07% |
50,699
| – | – |
|
74
Ventyx Biosciences
VTYX
$184M
| $420K | 0.06% |
192,647
-250,000
| -56% | -$545K |
|
|
ELEV
75
DELISTED
Elevation Oncology
ELEV
| $414K | 0.06% |
690,089
| – | – |
|